Background: Translating research, achieving impact, and assessing impact are important aspirations for all research collaboratives but can prove challenging. The Hunter Cancer Research Alliance (HCRA) was funded from 2014 to 2021 to enhance capacity and productivity in cancer research in a regional centre in Australia. This study aimed to assess the impact and benefit of the HCRA to help inform future research investments of this type.

Method: The Framework to Assess the Impact from Translational health research (FAIT) was selected as the preferred methodology. FAIT incorporates three validated methodologies for assessing impact: 1) Modified Payback; 2) Economic Analysis; and 3) Narrative overview and case studies. All three FAIT methods are underpinned by a Program Logic Model. Data were collected from HCRA and the University of Newcastle administrative records, directly from HCRA members, and website searches.

Results: In addition to advancing knowledge and providing capacity building support to members via grants, fellowships, scholarships, training, events and targeted translation support, key impacts of HCRA-member research teams included: (i) the establishment of a regional biobank that has distributed over 13,600 samples and became largely self-sustaining; (ii) conservatively leveraging $43.8 M (s.a.$20.5 M - $160.5 M) in funding and support from the initial $9.7 M investment; (iii) contributing to clinical practice guidelines and securing a patent for identification of stem cells for endometrial cell regeneration; (iv) shifting the treatment paradigm for all tumour types that rely on nerve cell innervation, (v) development and implementation of the world's first real-time patient treatment verification system (Watchdog); (vi) inventing the effective 'EAT' psychological intervention to improve nutrition and outcomes in people experiencing radiotherapy for head and neck cancer; (vi) developing effective interventions to reduce smoking rates among priority groups, currently being rolled out to disadvantaged populations in NSW; and (vii) establishing a Consumer Advisory Panel and Consumer Engagement Committee to increase consumer involvement in research.

Conclusion: Using FAIT methodology, we have demonstrated the significant impact and downstream benefits that can be achieved by the provision of infrastructure-type funding to regional and rural research collaboratives to help address inequities in research activity and health outcomes and demonstrates a positive return on investment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926601PMC
http://dx.doi.org/10.1186/s12913-024-10680-2DOI Listing

Publication Analysis

Top Keywords

fait methodology
8
assessing impact
8
assess impact
8
impact
7
fait
5
impact regionally
4
regionally based
4
based translational
4
cancer
4
translational cancer
4

Similar Publications

Objective: To report a 3-year follow-up from the FemoroAcetabular Impingement Trial, comparing arthroscopic surgery with physiotherapy in the management of femoroacetabular impingement (FAI) syndrome for the dual primary outcomes of radiographic hip osteoarthritis (OA) and patient-reported outcome measures of activities of daily living.

Methods: Two-group parallel, assessor-blinded, pragmatic randomised controlled trial across seven sites. 222 participants aged 18-60 years with FAI syndrome confirmed clinically and radiologically were randomised (1:1) to receive arthroscopic hip surgery (n=112) or physiotherapy (n=110).

View Article and Find Full Text PDF

[Not Available].

Bull Cancer

October 2024

Service de médecine nucléaire et UCP thyroïde, Centre François-Badesse, 3, avenue du Général-Harris, 14000 Caen, France.

Article Synopsis
  • Nuclear medicine continues to play a vital role in treating thyroid cancers, specifically through the use of iodine-131 (RAI) for differentiated thyroid cancer (DTC) and post-therapeutic scintigraphy to assess treatment response.
  • For challenging cases where RAI isn't effective, FDG PET imaging aids in diagnosis and prognosis, particularly for less than 5% of those with refractory disease and for aggressive anaplastic thyroid cancer.
  • Emerging theranostic strategies are being developed using various radiopharmaceuticals and imaging methods like 18F-DOPA, PSMA, and FAP, highlighting a shift from traditional treatments towards more personalized approaches in managing thyroid cancer.
View Article and Find Full Text PDF

[Not Available].

Bull Cancer

October 2024

Département d'imagerie, Service d'oncologie endocrinienne, Gustave-Roussy, Villejuif, F-94805, France. Electronic address:

LATEST DEVELOPMENTS IN ANAPLASTIC THYROID CARCINOMA MANAGEMENT IN 2024: Anaplastic thyroid carcinomas (ATCs) represent a rare and undifferentiated form of thyroid cancer with a poor prognosis, typically marked by a median overall survival of four to ten months. However, recent advances have shown improvements due to the more systematic application of molecular testing, targeted therapies, and immunotherapy, alongside the establishment of rapid specialized care protocols in expert centers. Clinically, ATCs often present as a rapidly enlarging cervical mass originating from the thyroid, causing neck, pain and tenderness, dyspnea and dys-phagia, and associated lymphadenopathy, typically in elderly patients.

View Article and Find Full Text PDF

[Not Available].

Bull Cancer

October 2024

Département d'oncologie et département de médecine nucléaire, Institut Bergonie, 33076 Bordeaux, France.

TREATING RADIO-IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN 2024: About 5 to 10% of patients with differentiated thyroid cancer (DTC) have advanced tumors at presentation or recurrence, with invasive cervical disease and/or distant metastases that cannot be effectively treated by conventional treatment, i.e. thyroid surgery and radioactive iodine.

View Article and Find Full Text PDF

[Not Available].

CMAJ

October 2024

Division d'immunologie clinique et d'allergie (Jeimy, Yu), Départment de médecine, Western University, London, Ont.; Division des allergies (Chan, Cook), Département de pédiatrie, University of British Columbia, BC Children's Hospital, Vancouver, C.-B.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!